BC Innovations | Dec 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest combinations of bispecific small molecules targeting fluorescein and CAIX, PSMA or FOLR1 plus anti-fluorescein CAR T cells could help treat triple-negative breast cancer (TNBC). The bispecific adapter molecules consist...
BC Week In Review | Oct 27, 2017
Company News

Fujirebio developing companion diagnostic for Morphotek's farletuzumab

The Morphotek Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523) granted Fujirebio Inc. (Tokyo, Japan) exclusive, worldwide rights to develop and commercialize the CA125 II assay as a companion diagnostic to identify ovarian cancer patients who...
BC Week In Review | Oct 10, 2016
Company News

Eisai, Eurofarma Laboratorios deal

Eisai’s Morphotek Inc. subsidiary granted Eurofarma exclusive, Latin American rights to develop and commercialize farletuzumab, a humanized IgG1 antibody targeting the folate receptor 1 ( FOLR1 ; FR-alpha ). The product is in a Phase II...
BC Week In Review | Dec 21, 2015
Company News

Eisai, University of Gothenburg deal

Eisai’s Morphotek Inc. subsidiary partnered with the Targeted Alpha Therapy (TAT) Group at the university to research and develop Eisai’s farletuzumab for radio-immunotherapy in ovarian cancer. The humanized IgG1 antibody targeting the folate receptor 1...
BC Week In Review | Apr 6, 2015
Clinical News

Farletuzumab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II 003-011 trial to evaluate 5 mg/kg IV farletuzumab weekly in combination with carboplatin and either paclitaxel or pegylated liposomal doxorubicin in about 210 patients...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps...
BC Week In Review | Jan 21, 2013
Clinical News

Farletuzumab: Preliminary Phase III data

Preliminary data from the double-blind, international Phase III Study FAR 131 (MORAb-003-004) trial in 1,100 patients with platinum-sensitive epithelial ovarian cancer in first relapse showed that IV farletuzumab plus carboplatin and taxane chemotherapy missed the...
BC Extra | Jan 15, 2013
Clinical News

Eisai's farletuzumab misses in ovarian cancer

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) said IV farletuzumab plus carboplatin and taxane chemotherapy missed the primary endpoint of improving progression-free survival (PFS) vs. placebo plus carboplatin and taxane chemotherapy in the Phase III FAR 131...
BC Week In Review | May 28, 2012
Clinical News

Farletuzumab: Phase I data

A single-arm, open-label Phase I trial in 15 patients with platinum-sensitive epithelial ovarian cancer showed that once-weekly 2.5 mg/kg farletuzumab plus carboplatin and pegylated liposomal doxorubicin every 4 weeks for 6 cycles produced 1 complete...
BC Week In Review | Apr 2, 2012
Clinical News

Farletuzumab: Completed Phase III enrollment

Eisai's Morphotek Inc. subsidiary completed enrollment of 1,080 patients in the double-blind, international Phase III FAR-131 trial comparing 1.25 and 2.5 mg/kg IV farletuzumab weekly in combination with carboplatin and taxane chemotherapy vs. carboplatin and...
Items per page:
1 - 10 of 32